ADL Amdl,

German Researchers Publish Results on AMDL's DR-70(R) Cancer Test Showing High Sensitivity TUSTIN, Calif. and FRANKFURT, Germany, Nov. 17 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, today announced that a new study by six researchers in the Medical Department, University Hospital, Frankfurt, Germany, determined that AMDL's DR-70(R) immunoassay "reliably differs between cancer patients and healthy controls." To evaluate DR-70(R), which quantifies fibrin degradation products given off by malignant cells into the bloodstream, the researchers used the blood of 85 patients with a known tumor and 100 healthy blood donors. The cancers included colorectal, stomach, pancreas, esophagus and cancer of the gastrointestinal tract. The German researchers determined that AMDL's DR-70(R) product "showed a good clinical performance with a sensitivity of 91 percent and a specificity of 93 percent." Patients with advanced tumors had significantly higher DR-70(R) scores. The researchers indicated that the DR-70(R) immunoassay may be useful as a prognostic factor in the clinical course of malignant diseases. The research appeared in Alimentary Pharmacology and Therapeutics, one of the top gastroenterological journals in the world, and is read especially by those in clinical practice. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdlcorporate.com/. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdlcorporate.com/

Copyright